EUCRW
Closed
Eucrates Biomedical Acquisition Corp
0.0031
-0.0019 (-38.00%)
Last Update: 26 Apr 2023 17:29:00
Yesterday: 0.005
Day's Range: 0. - 0.
Send
sign up or login to leave a comment!
When Written:
0.0405
Eucrates Biomedical Acquisition Corp is a special purpose acquisition company (SPAC) that was formed in 2021. The company was established with the goal of acquiring a business in the biomedical sector, including biotechnology, pharmaceuticals, medical devices, and healthcare services. The company is led by a team of experienced healthcare and finance professionals, including CEO Dr. Rajiv Shukla, who has over 20 years of experience in the healthcare industry.
Eucrates Biomedical Acquisition Corp is listed on the NASDAQ stock exchange under the ticker symbol "EUCRU". The company raised $100 million in its initial public offering (IPO) in March 2021, with the aim of using the funds to acquire a target company in the biomedical sector.
As a SPAC, Eucrates Biomedical Acquisition Corp has a limited lifespan and must acquire a target company within a certain timeframe, typically two years. If the company is unable to find a suitable acquisition target within this timeframe, it will be liquidated and the funds returned to investors.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Eucrates Biomedical Acquisition Corp is listed on the NASDAQ stock exchange under the ticker symbol "EUCRU". The company raised $100 million in its initial public offering (IPO) in March 2021, with the aim of using the funds to acquire a target company in the biomedical sector.
As a SPAC, Eucrates Biomedical Acquisition Corp has a limited lifespan and must acquire a target company within a certain timeframe, typically two years. If the company is unable to find a suitable acquisition target within this timeframe, it will be liquidated and the funds returned to investors.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








